Sana Biotechnology, Inc. (SANA) Stock Price & Analysis
Sana Biotechnology, Inc. (SANA) closed at USD 2.72 on Thursday, October 29, 2026, up 3.42% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 2.63; the Oct 29, 2026 session ranged USD 2.65–2.77 on volume of 3,307,850 shares. Market capitalization is $814.26M, with a 52-week range of USD 2.22–5.55 (NMS). Source: Nexqual, retrieved October 29, 2026 at 21:46 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SANA.md
Key facts (SANA)
- Analysts: Buy (mean 1.89 on a 1–5 scale) (9 analysts), mean target USD 8.43 (range 6–12).
- Total return with dividends: 1Y -44.5% vs S&P 500 +14.4%; 5Y -86.9% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.13, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SANA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$357M | -$273M | -$293M | -$273M | -$250M | -$219M |
| Net income | -$356M | -$269M | -$283M | -$267M | -$244M | -$212M |
| EPS (diluted) | -$2.14 | -$1.43 | -$1.46 | -$1.16 | -$0.96 | — |
| Free cash flow | -$281M | -$311M | -$274M | -$257M | -$145M | -$135M |
| Cash + short-term investments | $551M | $424M | $205M | $152M | $138M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SANA)
P/B 5.3x · FCF yield -16.59% · Earnings yield -26.01%
Analysts (SANA)
Consensus Buy (mean 1.89 on a 1–5 scale), 9 analysts; mean target USD 8.43 (low 6, high 12).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | B of A Securities | Target lowered | Buy | $7 → $6 |
Total return (dividends reinvested) (SANA)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -44.5% | -86.9% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | -44.6% | -33.3% |
| Volatility (annualized) | 75.1% | 98.3% |
| Max drawdown | -56.2% (Dec 2025→Oct 2026) | -93.5% (Nov 2021→Mar 2025) |
SANA earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 10, 2026 | Quarter ended Jun 30, 2026 | −$0.13 | −$0.12 | Miss −8.3% | +7.7% |
| May 11, 2026 | Quarter ended Mar 31, 2026 | −$0.14 | −$0.15 | Beat +6.7% | -7.1% |
| Mar 3, 2026 | Quarter ended Dec 31, 2025 | −$0.16 | −$0.13 | Miss −23.1% | -8.0% |
| Nov 6, 2025 | Quarter ended Sep 30, 2025 | −$0.15 | −$0.19 | Beat +21.1% | +0.2% |
| Aug 11, 2025 | — | — | — | — | +3.7% |
| Aug 6, 2025 | — | — | — | — | -30.3% |
| May 8, 2025 | — | — | — | — | +7.1% |
| Mar 17, 2025 | — | — | — | — | -22.2% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
SANA recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Sep 8, 2026 | 8-K | Regulation FD disclosure |
| Aug 14, 2026 | Schedule 13G/A | ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P.: 15.4% of shares, passive 5%+ holder (amended) |
| Aug 10, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 10, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
SANA suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Beam Therapeutics Inc. (BEAM) | “License Agreement with Beam” |
| Partner | Cobalt Biomedicine | “As a result of the Cobalt transaction, we obtained licenses to various technologies and intellectual property rights that relate to the development of our fusogen technology and related fusosome programs, including exclusive license agreements with Flagship Pioneering Innovations V, Inc. (Flagship) and La Societe Pulsalys (Pulsalys), as well as several exclusive options to enter into exclusive license agreements, …” |
| Partner | Flagship Pioneering Innovations V | “As a result of the Cobalt transaction, we obtained licenses to various technologies and intellectual property rights that relate to the development of our fusogen technology and related fusosome programs, including exclusive license agreements with Flagship Pioneering Innovations V, Inc. (Flagship) and La Societe Pulsalys (Pulsalys), as well as several exclusive options to enter into exclusive license agreements, …” |
| Competitor | AbbVie (ABBV) | “For example, we are aware that some of our competitors, including AbbVie Inc., Allogene Therapeutics, Inc., Aspect Biosystems Ltd., AstraZeneca PLC, Bristol-Myers Squibb Company, Cabaletta Bio, Inc., Caribou Biosciences, Inc., Century Therapeutics, Inc., CRISPR Therapeutics AG, Eli Lilly and Company, Gilead Sciences, Inc., Johnson & Johnson, Kelonia Therapeutics, Inc., Kyverna Therapeutics, Inc., Legend Biotech Co…” |
| Competitor | Eli Lilly (LLY) | “For example, we are aware that some of our competitors, including AbbVie Inc., Allogene Therapeutics, Inc., Aspect Biosystems Ltd., AstraZeneca PLC, Bristol-Myers Squibb Company, Cabaletta Bio, Inc., Caribou Biosciences, Inc., Century Therapeutics, Inc., CRISPR Therapeutics AG, Eli Lilly and Company, Gilead Sciences, Inc., Johnson & Johnson, Kelonia Therapeutics, Inc., Kyverna Therapeutics, Inc., Legend Biotech Co…” |
| Competitor | Johnson & Johnson (JNJ) | “For example, we are aware that some of our competitors, including AbbVie Inc., Allogene Therapeutics, Inc., Aspect Biosystems Ltd., AstraZeneca PLC, Bristol-Myers Squibb Company, Cabaletta Bio, Inc., Caribou Biosciences, Inc., Century Therapeutics, Inc., CRISPR Therapeutics AG, Eli Lilly and Company, Gilead Sciences, Inc., Johnson & Johnson, Kelonia Therapeutics, Inc., Kyverna Therapeutics, Inc., Legend Biotech Co…” |
Quoted from the company's 10-K filed Mar 3, 2026.
SANA company outlook (results filed Aug 10, 2026)
- “Sana expects to file an IND and begin a Phase 1/2 clinical trial for SC451 as early as this year. • SG293 is a CD8-targeted fusosome that delivers the genetic material to make CD19-directed CAR T cells.”
- “Sana expects to generate first-in-human data for SG293 in non-Hodgkin lymphoma as early as this year.”
- “Raised aggregate net proceeds of $93.3 million from sales of common stock through Sana's at-the-market offering facility (ATM) and Mayo Clinic investment in the second quarter; expected cash runway into mid-2027. • Raised net proceeds of $93.3 million in the second quarter from sales of common stock through Sana's ATM and equity financing.”
Quoted word-for-word from the SEC 8-K results press release.
SANA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.13 | $-0.12 | −$0.01 | $0 | 4 |
| Next quarter (ends Dec 2026) | $-0.16 | $-0.20 | +$0.04 | $0 | 4 |
| Current fiscal year (ends Dec 2026) | $-0.59 | $-0.60 | $0.00 | $0 | 4 |
| Next fiscal year (ends Dec 2027) | $-0.56 | $-0.54 | −$0.02 | $0 | 4 |
SANA options: expected move
Options price a move of about ±25.5% (±$0.70) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±10.8% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 128.0% | ±25.5% |
| Jan 15, 2027 | 78 | 115.7% | ±41.0% |
| Apr 16, 2027 | 169 | 117.1% | ±57.4% |
30-day implied volatility 102% vs 63.9% realized over the last 30 trading days. Put/call ratio (volume) 0.01. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 21:46 UTC)
| Price | USD 2.72 |
|---|---|
| Change | ▲ 3.42% (up) |
| Previous Close | USD 2.63 |
| Open | USD 2.65 |
| Day Range | USD 2.65 – 2.77 |
| 52-Week Range | USD 2.22 – 5.55 |
| Volume | 3,307,850 shares |
| Market Cap | $814.26M |
| Exchange | NMS |
Technical Analysis (SANA)
Nexqual's technical model rates SANA "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 21:46 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 52.7 (neutral) |
| vs SMA50 | Below (USD 3.07) |
| MACD | -0.14 (negative) |
Analyst Ratings (SANA)
Wall Street analysts rate SANA "Buy" based on 9 analysts, with a mean price target of USD 8.43 (range USD 6–12), per Nexqual as of October 29, 2026 at 21:46 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 8.43 |
| High Target | USD 12 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 8 / 1 / 0 |
Earnings (SANA)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.13 vs est -0.12 ▼ miss |
| 2026-03-31 | USD -0.14 vs est -0.15 ▲ beat |
| 2025-12-31 | USD -0.16 vs est -0.13 ▼ miss |
| 2025-09-30 | USD -0.15 vs est -0.19 ▲ beat |
Source: Nexqual, October 29, 2026 at 21:46 UTC.
Financials & Fundamentals (SANA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -152.87% |
| Debt / Equity | 0.52 |
| Current Ratio | 1.38 |
| Total Cash | $160.49M |
| Total Debt | $80.94M |
Source: Nexqual, October 29, 2026 at 21:46 UTC.
Financial Health Score (SANA)
Nexqual rates Sana Biotechnology, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 21:46 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $160M cash vs $81M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$144M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -137%, ROA -49.1% (last 4 quarters, SEC) |
Ownership (SANA)
| Insider Ownership | +6.08% |
|---|---|
| Institutional Ownership | +77.68% |
| Shares Outstanding | 299.36M |
| Float | 190.89M |
| Short % of Float | +23.03% |
Source: Nexqual, October 29, 2026 at 21:46 UTC.
Leadership (SANA)
Sana Biotechnology, Inc. is led by Steven D. Harr, President, CEO & Director, per Nexqual as of October 29, 2026 at 21:46 UTC.
| President, CEO & Director | Steven D. Harr |
|---|---|
| Executive VP & CFO | Brian D. Piper |
| Executive VP & Chief Scientific Officer | Dhavalkumar D. Patel |
| Senior Vice President, Clinical Lead, Hematology & Oncology Development | John Gerecitano |
Major Backers & Investors (SANA)
Notable institutional backers of Sana Biotechnology, Inc. include FMR, LLC, Flagship Pioneering LLC, RA Capital Management, L.P., according to Nexqual as of October 29, 2026 at 21:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 12.5% |
| Flagship Pioneering LLC | 8.35% |
| RA Capital Management, L.P. | 6.26% |
| Fidelity | 6.17% |
| Canada Pension Plan Investment Board | 3.41% |
| Bank of America Corporation | 1.92% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.57% |
| State Street | 3.74% |
| Vanguard Group | 2.8% |
| Geode Capital | 1.56% |
Source: Nexqual, October 29, 2026 at 21:46 UTC.
From Sana Biotechnology, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- With respect to our in vivo cell engineering research efforts, we have advanced from our earlier SG299 in vivo CAR T candidate to an improved next-generation product candidate, SG293, both of which use our proprietary fusogen-based delivery platform.
- We have built significant internal capabilities across a wide range of areas focused on solving the most critical limitations in engineering cells including: Stem Cell and Disease Biology.
- To demonstrate applicability in the context of the autoimmunity seen in people with T1D, we developed a proprietary mouse model in-house with human immune cells from a T1D patient.
- The safety data, secondary endpoints, dosing rationale, clinical outcomes, and immune analysis from the treated patient are discussed below in the section titled "Pancreatic Islet Cell Program." Our in vivo CAR T pipeline has advanced beyond our earlier constructs, such as SG299, to our next-generation product candidate, SG293, which leverages our proprietary fusogen delivery platform to enable direct, in-patient generation of CAR T cells.
Legal & Regulatory Risks (Item 1A, quoted)
- The lengthy approval process, as well as the unpredictability of clinical trial results, may prevent us from obtaining regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects.
- We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through accelerated approval pathways.
- We may in the future seek accelerated approval for one or more of our product candidates.
- The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 317.33 | ▼ 0.45% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 9.56 | ▼ 35.45% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| ABVX | Abivax SA | USD 89.06 | ▼ 0.87% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 21:46 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt